Insider Buying: The Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO, President Just Bought US$169k Worth Of Shares
Investors who take an interest in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) should definitely note that the CEO, President, Dinesh Patel, recently paid US$5.62 per share to buy US$169k worth of the stock. While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just 9.8%.
See our latest analysis for Protagonist Therapeutics
The Last 12 Months Of Insider Transactions At Protagonist Therapeutics
Notably, that recent purchase by Dinesh Patel is the biggest insider purchase of Protagonist Therapeutics shares that we've seen in the last year. Even though the purchase was made at a significantly lower price than the recent price (US$7.54), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
Over the last year, we can see that insiders have bought 69175 shares worth US$374k. On the other hand they divested 35345 shares, for US$290k. In the last twelve months there was more buying than selling by Protagonist Therapeutics insiders. You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Does Protagonist Therapeutics Boast High Insider Ownership?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Based on our data, Protagonist Therapeutics insiders have about 1.5% of the stock, worth approximately US$3.2m. I generally like to see higher levels of ownership.
What Might The Insider Transactions At Protagonist Therapeutics Tell Us?
It's certainly positive to see the recent insider purchases. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Protagonist Therapeutics stock. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
